CLDF Title
Home | Contact Us | Bookmark
Embassy of Education
Webcasts Abstract Library

Target Audience:

This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, and other healthcare professionals involved in the care of patients with cirrhosis.

Goal Statement:

The primary goal of this broadcast is to better understand how to diagnose, manage, and effectively treat patients with hepatorenal syndrome (HRS) and acute kidney injury (AKI) based on current guidelines and the latest clinical evidence.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Define the types of HRS and proposed pathophysiology
  • Discuss the International Club of Ascites (ICA) criteria for the diagnosis and management of AKI in cirrhosis and apply these criteria in clinical practice
  • Explain the therapies for HRS +/- AKI and apply recommended treatment strategies to clinical practice

For more information visit, email, or call 1-888-565-5321.

Provided by

Supported by an educational grant from Mallinckrodt Pharmaceuticals.

Hot Topics in Cirrhosis:






Hot Topics in Cirrhosis including the Impact of COVID-19 on the Liver


Case 1: HRS-AKI in a Patient with a History of Alcoholic Cirrhosis

David Bernstein, MD, FAASLD, FACG, FACP, AGAF

Case 2: HRS-CKD in a Patient with a History of NASH Cirrhosis

Catherine Frenette, MD, FAST, AGAF

Renal Health in Cirrhosis

Marcelo Kugelmas, MD, FAASLD, FACP

Panel Discussion/Q&A

Closing Remarks

Back to the Agenda

Sammy Saab, MD, MPH, AGAF, FACG, FAASLD (Chair)

Medical Director, Pfleger Liver Institute
Medical Director, Adult Liver Transplant Program
Chief, Transplant Hepatology
Head, Outcomes Research in Hepatology
Professor of Medicine and Surgery
Adjunct Professor of Nursing

Sammy Saab, MD, MPH is a professor in the Departments of Internal Medicine and Surgery at the David Geffen School of Medicine University of California Los Angeles (UCLA) and an adjunct professor of nursing at UCLA School of Nursing. He is currently the medical director of the UCLA Adult Liver Transplant Program, medical director and the Pfleger Liver Institute, and the chief of Transplant Hepatology. Dr. Saab is also the head of Outcomes Research in Hepatology at the Pfleger Liver Institute. He is also received his BS, MD, and MPH from UCLA. Dr. Saab completed his residency in internal medicine at the University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at UCLA Center for Health Sciences. Dr. Saab is board certified in gastroenterology and transplant hepatology. He has received honorary fellowships from the American Gastroenterology Association (AGAF), the American College of Gastroenterology (FACG), and the American Association for the Study of Liver Diseases (FAASLD).

Dr. Saab is active in many local, national, and international committees, including the Medical Advisory Committee of the Los Angeles Chapter of the American Liver Foundation. He also served on the Practice Guidelines Committee of the American Society of Transplantation and the Educational Committee of the American Association for the Study of Liver Diseases. Dr. Saab was also a member of the American Association for the Study of Liver Diseases Nominating Committee. He has been an investigator in numerous clinical trials, a frequently invited speaker worldwide, and leads an annual patient education seminar. He has been awarded one of "The Best Doctors in America," received the Distinguished Achievement Award from his Division of Digestive Diseases, and was awarded an honorary fellowship degree from the American Gastroenterological Association.

Dr. Saab has published almost 300 peer-reviewed manuscripts. He has also authored many book chapters, editorials, abstracts, and poster presentations. Dr. Saab is on the editorial board of over a dozen journals and is the associate editor for liver for the Journal of Clinical Gastroenterology.


Speaker Bureau: AbbVie, Bristol Myers Squibb, Bayer, Eisai, Exelixis, Gilead, Intercept, and Salix

Advisor: AbbVie, Bayer, Eisai, Exelixis, Gilead, Intercept, and Salix

Honorarium Recipient: AbbVie, Bristol Myers Squibb, Bayer, Eisai, Exelixis, Gilead, Intercept, and Salix

Back to the Agenda

David Bernstein, MD, FAASLD, FACG, FACP, AGAF

Vice Chair of Medicine for Clinical Trials
Chief of Hepatology and Director, Sandra Atlas Bass Center for Liver Diseases
Northwell Health
Professor of Medicine and Education Science
Zucker School of Medicine at Hofstra/Northwell
Roslyn, New York

David E. Bernstein, MD is Vice Chair of Clinical Trials in the Department of Medicine, Chief, Division of Hepatology and Director of the Sandra Atlas Bass Center for Liver Diseases and Head of the Liver Sub-Specialty Service Line for the Northwell Health System. He is the Professor of Medicine and Education at the Zucker School of Medicine at Hofstra/Northwell. Dr Bernstein has extensive experience in the academic setting, as well as developing and implementing policies and best practices in gastroenterology for hospital and outpatient care.

Dr. Bernstein graduated from SUNY-Stony Brook School of Medicine in 1988. Following graduation from SUNY-Stony Brook School of Medicine, he completed his medical residency at Montefiore Medical Center and his fellowship in Gastroenterology and Hepatology at the University of Miami Affiliated Hospitals under the direction of Dr Eugene Schiff.

After completing his Fellowship, Dr. Bernstein joined the faculty of the University of Miami in the Division of Hepatology. At the University of Miami, he started his career as a clinician, teacher and researcher.

Dr. Bernstein's main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C. Since 1994, he has been involved in designing programs for the treatment of hepatitis C and has been an influential national and international leader in this field. He is the author of over 100 publications, 10 book chapters, and has been the principle investigator in more than 240 clinical trials. His work has been published in such prestigious journals as the New England Journal of Medicine and The Lancet. He regularly is asked to lecture about this topic on Long Island, across the nation and around the globe. His research has led to the development of new medications which are able to cure more than 95% of patients with hepatitis C infection and in the future could lead to the eradication of hepatitis C infection in the United States.

He currently serves as a reviewer for several journals including American Family Physician, the American Journal of Gastroenterology, Annals of Internal Medicine, Federal Practitioner, Gastroenterology, Gastrointestinal Endoscopy, Hepatology, Internal Medicine, the Journal of Hepatology, the Journal of Substance Abuse Treatment, Medical Science Monitor, and PharmacoEconomics.

Dr. Bernstein has made numerous presentations as a lecturer and keynote speaker on hepatitis, cirrhosis, and liver transplantation throughout the world. Dr. Bernstein is active in many national and international societies and has held elective office in many of them. He is a former President of the Bockus International Society of Gastroenterology and of the New York Gastrointestinal Society. He is currently the Treasurer of the Bockus International Society of Gastroenterology. He served for six years as the American College of Gastroenterology Governor for Long Island. He has served on numerous committees of the American Association for the Study of Liver Diseases and the American College of Gastroenterology. He is also a member of the European Society for the Study of Liver Diseases, the Asia-Pacific Association for the Study of Liver Diseases. He is a fellow of the American Association for the Study of Liver Diseases, the American College of Gastroenterology and the American College of Physicians.

Dr. Bernstein has been involved in shaping public policy and education regarding liver diseases. He serves as a special consultant to the New York State Department of Health and in that role has helped develop and implement New York State's 5-year Strategic Plan for Viral Hepatitis as well as lead the group developing guidelines to be used for the treatment of hepatitis C in New York State. He regularly leads telemedicine conferences for public health providers, prison health providers and federally qualified health care centers to educate these providers and has made himself available as a special consultant to these centers for individual cases questions.

Since 1999, he has written regular columns under the masthead "Liver Lines" and "The Specialist" in the Anton Community Newspapers on Long Island to better educate the public about all aspects of liver disease in the hopes of bringing a better understanding of these diseases and issues to the local population.

In an effort to improve provider education and educate local and state governments on the overall health care burden of liver diseases, Dr. Bernstein organized his colleagues across New York State and founded the Empire Liver Foundation in 2013. The Empire Liver Foundation, comprised of more than 90% of the practicing liver doctors in New York State, has quickly become the premier liver organization in the state and is looked to regularly by the New York City and State Department of Health to provide consultation on liver related issues.

Dr. Bernstein has developed a reputation as an outstanding clinician. In addition to all the work listed above, Dr. Bernstein maintains a busy clinical practice in the field of hepatology. He is well respected by his fellow physicians and by his patients. Over the years, he has helped improve the quality of life thousands of patients and their families in the area which he serves. Castle-Connelly has recognized him as one the Best Doctors since 2006.


Research support: Bausch, Enanta, Gilead, GSK, La Jolla, NovoNordisk, Novartis, Syneos, Pfizer, and Protogonist.

Consultant: AbbVie, Dova, Gilead, and Shinoigi.

Back to the Agenda

Catherine Frenette, MD, FAST, AGAF

Medical Director of Liver Transplantation
Scripps Center for Organ Transplantation
Scripps Green Hospital
Director, Liver and Hepatocellular Cancer Program
Scripps MD Anderson Cancer Center
La Jolla, California

Catherine Frenette, MD underwent medical training at Rush Medical College in Chicago, IL. She then completed internal medicine training at Scripps Mercy Hospital in San Diego, CA, and subsequently underwent training in gastroenterology with a focus on transplant hepatology at Scripps Clinic in La Jolla, CA. Dr. Frenette currently works at the Scripps Clinic Center for Organ and Cell Transplantation where she is the medical director of liver transplantation. She is also the medical director of the Liver and Hepatocellular Cancer Program at the Scripps MD Anderson Cancer Center. Dr. Frenette has several active research trials, as well as serves in a teaching capacity for the residents and fellows at Scripps Clinic. Dr. Frenette holds special clinical interest and expertise in liver transplantation to treat cirrhosis, hepatocellular carcinoma, autoimmune hepatitis, viral hepatitis, acute liver failure, and end-stage liver disease. She is a well-known expert in the treatment of all stages of hepatocellular carcinoma and has done multiple national and international educational sessions on this topic. She has been awarded fellow status of the American Society of Transplantation and has also been awarded fellow of the American Gastroenterology Association.


Speaker's Bureau: AbbVie, Bayer, Bristol Meyers Squibb, Eisai, Exelixis, Gilead, Intercept, Salix, and Shionogi.

Consultant: Bayer, Conatus, Eisai, Genentech, and Merck.

Research Support: Bayer, Conatus, Genfit, and Merck.

Advisory Board: Gilead, Eisai, Exelixis, Genentech, Merck, and Wako.

Back to the Agenda

Marcelo Kugelmas, MD, FAASLD, FACP

Director of Hepatology and Research
South Denver Gastroenterology
Englewood, Colorado

Marcelo Kugelmas, MD received his medical degree with honors from the University of Buenos Aires. After his internship and internal medicine residency at the University of Southern California-Los Angeles County Hospital in Los Angeles, he went to Cleveland, Ohio where he completed his gastroenterology fellowship at the Cleveland Clinic Foundation and served as chief fellow in 1995. He then moved to Lexington, Kentucky where he pursued further training in hepatology, liver transplantation, and advanced endoscopy and remained there until 2000 as an assistant professor. He then moved to Colorado, where he joined the University of Colorado Liver Section. Over the last 20 years, Dr. Kugelmas' main focus has been on the care of patients with liver diseases. He became an associate professor of medicine in 2004, before joining South Denver Gastroenterology. Dr. Kugelmas is a national lecturer on topics of chronic liver disease, has presented regularly at multiple gastroenterology, liver, and transplantation annual meetings, and has published over 35 papers in peer-viewed journals.


Consultant: Mallinckrodt Pharmaceuticals.


Be the first to know about our latest upcoming programs and events!


Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.